Treatment possibilities for primary biliary cholangitis (PBC) continue to expand, with encouraging data on obeticholic acid and fibrates, as well as pilot studies that suggest a benefit role for biological agents that focus on the immune defects that occur in the disease. Investigators are looking into the possible value of new monoclonal antibodies to address those immunological abnormalities, according to a recent review; other potential treatment options include drugs that modulate cholestasis.

The literature review also discusses the long-term benefits of ursodeoxycholic acid, which has been associated with excellent transplant free survival in this patient population.